Cargando…

MEK1 drives oncogenic signaling and interacts with PARP1 for genomic and metabolic homeostasis in malignant pleural mesothelioma

Malignant pleural mesothelioma (MPM) is a lethal malignancy etiologically caused by asbestos exposure, for which there are few effective treatment options. Although asbestos carcinogenesis is associated with reactive oxygen species (ROS), the bona fide oncogenic signaling pathways that regulate ROS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Haitang, Gao, Yanyun, Xu, Duo, Xu, Ke, Liang, Shun-Qing, Yang, Zhang, Scherz, Amina, Hall, Sean R. R., Forster, Stefan, Berezowska, Sabina, Yao, Feng, Ochsenbein, Adrian F., Marti, Thomas M., Kocher, Gregor J., Schmid, Ralph A., Dorn, Patrick, Peng, Ren-Wang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9918536/ https://www.ncbi.nlm.nih.gov/pubmed/36765038 http://dx.doi.org/10.1038/s41420-023-01307-2

Ejemplares similares

Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural Mesothelioma
por: Xu, Duo, et al.
Publicado: (2019)

Malignant pleural mesothelioma co-opts BCL-X(L) and autophagy to escape apoptosis
por: Xu, Duo, et al.
Publicado: (2021)

Tumor-infiltrating lymphocytes are functionally inactivated by CD90+ stromal cells and reactivated by combined Ibrutinib and Rapamycin in human pleural mesothelioma
por: Yang, Haitang, et al.
Publicado: (2022)

Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma
por: Xu, Duo, et al.
Publicado: (2018)

Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma
por: Yang, Haitang, et al.
Publicado: (2020)

Therapeutic Landscape of Malignant Pleural Mesothelioma: Collateral Vulnerabilities and Evolutionary Dependencies in the Spotlight
por: Xu, Duo, et al.
Publicado: (2020)

Schedule-Dependent Treatment Increases Chemotherapy Efficacy in Malignant Pleural Mesothelioma
por: Karatkevich, Darya, et al.
Publicado: (2022)

Systematic Analysis of Aberrant Biochemical Networks and Potential Drug Vulnerabilities Induced by Tumor Suppressor Loss in Malignant Pleural Mesothelioma
por: Yang, Haitang, et al.
Publicado: (2020)

The effect of neoadjuvant therapy on PD-L1 expression and CD8+lymphocyte density in non-small cell lung cancer
por: Zens, Philipp, et al.
Publicado: (2022)

Cul4A is an oncogene in malignant pleural mesothelioma
por: Hung, Ming-Szu, et al.
Publicado: (2011)

Comparison of the 7th and 8th Edition of the UICC/AJCC TNM Staging System in Primary Resected Squamous Cell Carcinomas of the Lung—A Single Center Analysis of 354 Cases
por: Neppl, Christina, et al.
Publicado: (2019)

Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition
por: Srinivasan, Gayathri, et al.
Publicado: (2017)

A prognostic score for non-small cell lung cancer resected after neoadjuvant therapy in comparison with the tumor-node-metastases classification and major pathological response
por: Zens, Philipp, et al.
Publicado: (2021)

Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5′-deoxy-5-fluorocytidine (5′-DFCR)
por: Gao, Yanyun, et al.
Publicado: (2021)

Organoids as a Model for Precision Medicine in Malignant Pleural Mesothelioma: Where Are We Today?
por: Gao, Yanyun, et al.
Publicado: (2022)

NF2 and Canonical Hippo-YAP Pathway Define Distinct Tumor Subsets Characterized by Different Immune Deficiency and Treatment Implications in Human Pleural Mesothelioma
por: Yang, Haitang, et al.
Publicado: (2021)

Chaperone-Mediated Autophagy Markers LAMP2A and HSPA8 in Advanced Non-Small Cell Lung Cancer after Neoadjuvant Therapy
por: Losmanova, Tereza, et al.
Publicado: (2021)

Peritumoral CD90+CD73+ cells possess immunosuppressive features in human non-small cell lung cancer
por: Wang, Limei, et al.
Publicado: (2021)

HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer
por: Yang, Haitang, et al.
Publicado: (2019)

Antitumor activity of MEK and PI3K inhibitors against malignant pleural mesothelioma cells in vitro and in vivo
por: MIYOSHI, SEIGO, et al.
Publicado: (2012)

Malignant pleural mesothelioma
por: Rao, Sukhesh
Publicado: (2009)

Targeting YAP in malignant pleural mesothelioma
por: Zhang, Wen‐Qian, et al.
Publicado: (2017)

Epidemiology, diagnosis and treatment of the malignant pleural mesothelioma, a narrative review of literature
por: Schumann, Sven Oliver, et al.
Publicado: (2021)

Human lung-derived mesenchymal stem cell-conditioned medium exerts in vitro antitumor effects in malignant pleural mesothelioma cell lines
por: Cortes-Dericks, Lourdes, et al.
Publicado: (2016)

Malignant pleural mesothelioma with resolution of pleural effusion
por: Nishida, Sayaka, et al.
Publicado: (2023)

Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers
por: Sorino, Claudio, et al.
Publicado: (2023)

Tumor Initiation Capacity and Therapy Resistance Are Differential Features of EMT-Related Subpopulations in the NSCLC Cell Line A549()
por: Tièche, Colin Charles, et al.
Publicado: (2018)

EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma
por: Tan, Yi-Hung Carol, et al.
Publicado: (2019)

Functional and molecular characterization of PD1(+) tumor-infiltrating lymphocytes from lung cancer patients
por: Lipp, Jesse J., et al.
Publicado: (2022)

Malignant pleural mesothelioma in Italy
por: Bianchi, Claudio, et al.
Publicado: (2009)

Pleural mesothelioma – case report
por: Klawiter, Anna, et al.
Publicado: (2010)

Heterogeneity in Malignant Pleural Mesothelioma
por: Oehl, Kathrin, et al.
Publicado: (2018)

Immunotherapy in Malignant Pleural Mesothelioma
por: de Gooijer, Cornedine J., et al.
Publicado: (2020)

Malignant pleural mesothelioma: an update
por: Hajj, Glaucia N. M., et al.
Publicado: (2021)

Malignant pleural mesothelioma in situ
por: Ando, Kohei, et al.
Publicado: (2022)

Extrathoracic Metastases in Pleural Mesothelioma
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2023)

Pleural Mesothelioma in the Era of Immunotherapy
por: Chevallier, Mathieu, et al.
Publicado: (2023)

Surgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma
por: Woodard, Gavitt A., et al.
Publicado: (2020)

Blocking the epithelial-to-mesenchymal transition pathway abrogates resistance to anti-folate chemotherapy in lung cancer
por: Liang, S-Q, et al.
Publicado: (2015)

Programmed Death-Ligand 1 Expression in Lung Cancer and Paired Brain Metastases—a Single-Center Study in 190 Patients
por: Kündig, Alexandra, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qfetp9mucr1p6v9pa7urfq2gm0